It’s not every day that two health systems partner to develop a commercially available software solution. But NYU Langone Health and Dana-Farber Cancer Institute have formed a strategic collaboration to co-develop the Solavia Decision Suite, an oncology support platform designed to improve cancer care for patients and clinicians alike. 

The collaboration is seeking to build a modern oncology decision tool that supports precise, evidence-based, and standardized care delivery at scale.

Solavia launched internally at NYU Langone on June 30 and is now commercially available. The organizations say the application combines the platform development credentials of NYU Langone’s information technology capabilities with Dana-Farber’s track record and clinical expertise in oncology pathways. 

By first implementing and refining Solavia within its own health system, NYU Langone says it is helping ensure the platform is both practical and effective in real-world care delivery, with plans to expand adoption to additional organizations.

“Solavia represents an important opportunity to deploy the next generation of oncology decision support for clinicians and patients,” said Nader Mherabi, executive vice president, vice dean, and chief digital and information officer at NYU Langone, in a statement. “By co-developing this platform with Dana-Farber, we are translating clinical expertise into a scalable strategic capability that can improve consistency in care and accelerate the adoption of the latest evidence in oncology practice.”

Embedded directly in the EHR, Solavia provides physicians with seamless access to the latest evidence, biomarkers, guidelines, and therapeutic options so they can provide top-quality patient care and conduct impactful research in a fast-changing oncology landscape. Solavia is expected to strengthen care standardization, reduce unnecessary variation in care delivery, and improve the way care pathways are managed.

“Solavia is designed with clinicians in mind and patients at the center,” said David Jackman, M.D., medical director of clinical pathways and new business initiatives at Boston-based Dana-Farber, in a statement. “The platform is intended to support care teams with evidence-based, context-aware guidance that helps make cancer treatment more personalized, coordinated, and consistent.”